Silence Therapeutics

Strategic and capital-allocation decisions are made by CEO Craig Tooman and the board of directors, with ultimate accountability to public shareholders under UK and US securities regulations. The firm is not governed by a family council or a single principal. Major pipeline moves and partnership terms are disclosed per London and Nasdaq listing rules.

The lead asset is zerlasiran, a siRNA therapy that targets the LPA gene to reduce lipoprotein(a) levels. It is currently in Phase 3 clinical trials. Silence out-licensed regional rights to AstraZeneca for most global markets and to Hansoh Pharma for Greater China, retaining rights in certain territories while earning milestone payments and royalties on future sales (per the firm, 2020–2021).

Silence generates its own pipeline internally using the mRNAi GOLD platform, a proprietary technology for designing and delivering GalNAc-conjugated siRNAs to hepatocytes. The firm does not acquire external programs; preclinical and clinical assets come from internal discovery work run out of its Berlin laboratory (per the firm's scientific publications and pipeline disclosures).

No. Silence is an operating biotechnology company. It deploys its cash into its own drug discovery, clinical trials, and platform science — not into venture capital funds, private equity, or direct co-investments alongside external GPs. Its treasury serves to fund research and development and general corporate purposes.

The firm focuses exclusively on diseases with validated liver-expressed gene targets where GalNAc-mediated siRNA delivery applies. It does not pursue central nervous system disorders, solid tumors outside hepatocyte biology, or non-genetic targets. Its public pipeline is confined to hematology, cardiovascular disease, and iron-overload disorders — a deliberate exclusion of wider therapeutic areas (per the firm's pipeline disclosures).